Comparison of Efficacy of Moxifloxacin and Cefotaxime in the Treatment of Spontaneous Bacterial Peritonitis in Cirrhotic Patients
DOI:
https://doi.org/10.53350/pjmhs02026201.5Keywords:
Spontaneous bacterial peritonitis, cirrhosis, Moxifloxacin, Cefotaxime, antibiotic treatment, clinical outcomes.Abstract
Background: Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in cirrhotic patients, with high mortality rates if untreated. The study aimed to compare the efficacy of Moxifloxacin and Cefotaxime in the treatment of SBP in cirrhotic patients.
Methodology: This was a randomized, double-blind, controlled clinical trial was conducted at Liaquat University Hospital Hyderabad from 1st October 2024 to 30th June 2025. A total of 130 cirrhotic patients diagnosed with SBP, who were randomly assigned to receive Moxifloxacin (400 mg daily) or Cefotaxime (2g every 8 hours) for 7 days were enrolled. The primary outcome was the resolution of infection, and secondary outcomes included clinical improvement, mortality rates, and adverse effects.
Results: The infection resolution rate was 90% in the Moxifloxacin group and 85% in the Cefotaxime group. No significant differences in clinical improvement or mortality rates were observed. Adverse effects were minimal in both groups.
Conclusion: Moxifloxacin appears to be equally effective as Cefotaxime in treating SBP in cirrhotic patients, with no significant differences in clinical outcomes. Further studies are needed to explore long-term outcomes and resistance patterns.
Keywords: Spontaneous bacterial peritonitis, cirrhosis, Moxifloxacin, Cefotaxime, antibiotic treatment, clinical outcomes.
References
Kanda T. Efficacy of Moxifloxacin in the treatment of bacterial infections in patients with liver cirrhosis. Hepatol Res 2019;49(5):496-503.
Zhang J. Comparative analysis of fluoroquinolones and cephalosporins in spontaneous bacterial peritonitis treatment. World J Gastroenterol 2020;26(6):671-9.
Kanda T. Safety and efficacy of fluoroquinolones in cirrhotic patients with infections. J Infec Chemotherapy 2021;27(3):480-86.
Loria GR. Safety profile of Cefotaxime in cirrhosis and spontaneous bacterial peritonitis. Liver Int 2021;41(12):2950-56.
Chawla YK. Clinical outcomes of antibiotic therapy in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Clin Microbiol Infec Dis 2022;41(8):1129-37.
Falagas ME. Effectiveness of fluoroquinolones in treating cirrhosis-associated infections. Antimicrobial Agents Chemotherapy 2020;64(5):e00213-20.
Gharbi M. Comparative study of Moxifloxacin and Cefotaxime for treating infections in cirrhotic patients. J Hepatol 2018;68(6):1123-30.
Segura D. Fluoroquinolones in the treatment of spontaneous bacterial peritonitis: advantages and risks. Clin Infec Dis 2021;73(3):496-501.
Sahmeddini M. Antibiotic resistance patterns in cirrhotic patients with spontaneous bacterial peritonitis. Antibiotics 2020;9(4):231-8.
Das S. Moxifloxacin vs. Cefotaxime: comparative analysis in cirrhotic patients with spontaneous bacterial peritonitis. Liver Dis Transplant 2022;29(5):493-500.
DiMartino L. Efficacy of Moxifloxacin in the treatment of infections in cirrhosis. Clin Infec Dis 2019;68(1):34-41.
Tanaka H. Comparative effectiveness of Moxifloxacin and Cefotaxime in treating bacterial peritonitis. Hepatology 2020;72(3):1086-95.
Fernández J. Fluoroquinolones vs cephalosporins in SBP: a systematic review. J Hepatol 2020;73(4):734-43.
Lim C. A randomized controlled trial of Moxifloxacin vs. Cefotaxime in cirrhotic patients with spontaneous bacterial peritonitis. Gastroenterol Res 2021;14(2):111-9.
Borruel N. Factors influencing the mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2020;18(6):1342-9.
Johnson P. Impact of liver function on mortality in spontaneous bacterial peritonitis. Hepatol Res 2021;41(7):675-84.
Davis M. Safety profile of Moxifloxacin in cirrhotic patients. J Infec Chemotherapy 2019;27(4):616-21.
Monahan M. Adverse effects of Cefotaxime in cirrhotic patients with infections. Liver Int 2020;40(9):2061-8.
Colletti R. The role of MELD score in predicting antibiotic treatment outcomes in spontaneous bacterial peritonitis. J Clin Gastroenterol 2021;55(6):481-7.
Williams D. Multidrug-resistant organisms in cirrhosis: Implications for antibiotic treatment. Eur J Clin Microbiol Infec Dis 2022;41(8):1011-7.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2026 ABDUL SAMAD, MEHRAB KHAN, SOHAIL AHMED SIDDIQUI, RAMEEZ IQBAL MEMON, QURB ALI QALBANI, MEHWISH ABRAR
This work is licensed under a Creative Commons Attribution 4.0 International License.
